Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202773 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Rheumatoid Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT01202773 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 456 participants.
The verdict
NCT01202773, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α) inhibitors. This study is comprised of 2 periods: Period 1: 24-week blinded treatment Period 2: 48-week post-treatment follow-up
Interventions
- DRUG LY2127399
- DRUG Placebo Q4W
- DRUG Placebo Q2W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202773
The ClinicalTrials.gov registry entry for NCT01202773 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY2127399 is the first listed.
NCT01202773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202773 about?
NCT01202773 is a clinical study titled "A Study in Participants With Rheumatoid Arthritis". The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α) inhibitors. This study is comprised of 2 periods: Period 1: 24-week blinded...
What is the current status of trial NCT01202773?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2011-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01202773?
The interventions under investigation include: LY2127399 (DRUG), Placebo Q4W (DRUG), Placebo Q2W (DRUG).
Who is sponsoring clinical trial NCT01202773?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.